Home
overview

It had been predicted that the market for anti-arthritic drugs would exceed more than $20 billion in the next few years. However, with recent safety concerns over the use of Cox-2 inhibitors, the growth of this market has become a topic of great controversy, with the future development and use of Non-Steroidal Anti-Inflammatory (NSAIDs) being somewhat uncertain.

To learn more, join us for the opportunity to discuss the latest issues surrounding the current arthritis market, including updates on both existing and novel treatments available, illustrative case studies examining the strategies of all the major players in the auto-immunity field and the future of Cox-2 inhibitors. Hear from leading experts from major pharmaceutical companies and serious academic leaders as they assess the latest enthusiasm for DMARD therapy, including the potential for combination treatment, advances in target identification and validation and the development of novel anti-arthritic drugs. This event will also consider the latest regulatory guidelines, updates on research and effective clinical trial design for both osteo and rheumatoid arthritis.

A unique opportunity to learn from leading industry experts including:
Dr Stephen Myers, Acting Medical Director, Musculoskeletal Programs, Eli Lilly
Dr Christian Antoni, Group Director, Clinical Immunology, Schering-Plough
Dr Heather Raymon, Associate Director, in vivo Pharmacology, Celgene
Adrian Moore, Senior Inflammation Pharmacologist, Celltech
Dr Elena Izmailova, Scientist, Millennium Pharmaceuticals
Professor David Isenberg, Academic Director, Rheumatology, University College London
Professor Gabriel Panayi, ARC Professor, Rheumatology, King’s College London

Programme highlights include:

TRENDS IN THE TREATMENT OF ARTHRITIS:
Assess the latest developments and changing dynamics in the arthritis market
THE FUTURE OF COX-2:
Understand the regulatory guidelines and the impact of recent developments
NOVEL AGENTS IN THE TREATMENT OF RA: A comprehensive overview of developed and emerging therapies and the likely impact on the RA treatment paradigm
BINDING IMMUNOGLOBULIN PROTEIN (BIP): An update on the latest developments and the associated benefits of the treatment
INDUSTRY EXPERTS: Meet the key decision-makers and make valuable industry contacts

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Jorgen Petersen

Jorgen Petersen, Senior Medical Director, Genmab

9:10 KEYNOTE ADDRESS

David Isenberg

David Isenberg, Academic Director, Rheumatology, University College London

  • Recent findings in novel therapeutic targets
  • Assessing the drug classes currently on the market
  • Predictions for the future of arthritis treatment
  • Raising awareness of clinical trial results and issues in drug safety
  • 9:50 THE FUTURE OF COX-2

    Clare Churchill

    Clare Churchill, Healthcare Analyst, DataMonitor

  • Understanding the regulatory guidelines and implications
  • Assessing the impact on the market
  • Optimising future agents
  • The future of COX-2’s
  • 10:30 Morning Coffee

    11:00 PANEL DISCUSSION

  • Assessing the findings of the study
  • Will the axe fall on COX-2’s?
  • Predictions for 2005 and beyond
  • David Isenberg

    David Isenberg, Academic Director, Rheumatology, University College London

    Christian Antoni

    Christian Antoni, Group Director, Clinical Immunology, Schering Plough

    Melissa Stolper

    Melissa Stolper, Analyst, Decision Resources

    11:40 MARKET OPPORTUNITIES FOR RHEUMATOID ARTHRITIS DRUGS

    Melissa Stolper

    Melissa Stolper, Analyst, Decision Resources

  • Future trends in RA epidemiology
  • Current treatment options and medical practice
  • Unmet needs and untapped areas of opportunity
  • Emerging therapies and their potential impact on the RA treatment paradigm
  • Market dynamics and the future outlook for the RA market
  • 12:20 Networking Lunch

    13:50 DRUG DISCOVERY IN RHEUMATOID ARTHRITIS TREATMENT

    Stephen Myers

    Stephen Myers, Acting Medical Director, Musculoskeletal Programmes, Eli Lilly & Company

  • The current situation with anti-TNF and the implications for alternative drugs
  • Current treatment options
  • Combination therapies and trial results
  • Development opportunities
  • 14:30 REMICADE IN THE TREATMENT OF RHEUMATOID ARTHRITIS

    15:10 Afternoon Tea

    15:40 NOVEL DRUG USE IN RHEUMATOID ARTHRITIS

    Adrian Moore

    Adrian Moore, Senior Inflammation Pharmacologist, Celltech

  • Identification
  • Potency & selectivity
  • Metabolism & Pharmacokinetics
  • Anti-inflammatory activity in-vivo
  • 16:20 DRUG DEVELOPMENT IN RA – RhuDex

    Neill Moray MacKenzie

    Neill Moray MacKenzie, Chief Business Officer, Avidex

  • Development of the first-in-class small molecule CD80
  • New orally available drug for RA
  • Novel ‘co-stimulation’ modifier
  • Assessing the outlook for RA treatment
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Jorgen Petersen

    Jorgen Petersen, Senior Medical Director, Genmab

    9:10 THE IDENTIFICATION OF PROTEIN BIOMARKERS

    Elena Izmailova

    Elena Izmailova, Scientist, Millennium Pharmaceuticals

  • Early detection of rheumatoid arthritis
  • Details of the study and the implications
  • The role of drug development
  • The effect on clinical trials
  • 9:50 ORAL THERAPY FOR RHEUMATOID ARTHRITIS

    Mladen Mercep

    Mladen Mercep, Inflammation-Immunology Programmes Director, PLIVA

  • Discovery of new class of TNF-a inhibitors with novel mechanism of action
  • In vitro and in vivo effects on LPS induced TNF-a production
  • Efficacy in rodent models of inflammation and RA
  • Analgesic activity
  • Preclinical development and in vivo effects on LPS induced
  • 10:30 Morning Coffee

    11:00 MRI

    Saara Totterman

    Saara Totterman, Chief Medical Officer, Virtual Scopics L L C

  • Image analysis technology for OA
  • Quantitative cartilage image-based biomarkers
  • Quantitative non-cartilage image-based biomarkers
  • Clinical trials in OA using quantitative MRI image analysis
  • 11:40 BINDING IMMUNOGLOBULIN PROTEIN (BIP)

    Gabriel Panayi

    Gabriel Panayi, ARC Professor, Rhuematology, Department of Rheumatology, Kings College London

  • Updates on what has been learnt in the last year
  • Assessing the associated benefits of the treatment
  • Meeting the needs of the research and patient
  • 12:20 Networking Lunch

    13:50 SMALL MOLECULE KINASE

    Heather Raymon

    Heather Raymon, Associate Director, In Vivo Pharmacology, Celgene

  • Overview of kinase pathways involved
  • Potential kinase targets
  • Data from preclinical models of arthritis
  • 14:30 DRUG DEVELOPMENT IN THE TREATMENT OF OA

    Ennio Ongini

    Ennio Ongini, Head Research , Nicox

  • Role of nitric oxide (NO) in gastrointestinal and cardiovascular systems
  • Discovery of CINODs (Cox Inhibiting Nitric Oxide Donators)
  • Profile of the lead compound HCT 3012
  • Clinical data in osteoarthritis (OA) pain
  • Clinical data on gastrointestinal and cardiovascular safety
  • CINOD: a unique opportunity in the new environment
  • 15:10 Afternoon Tea

    15:40 DRUG SCREENING

    Paul Garside

    Paul Garside, Member, Scientific Board, MD Biosciences

  • Why it is important to screen immunomodulators in vivo
  • How to screen immunomodulators in vivo
  • Recent advances in screening immunomodulators in vivo
  • The future of screening immunomodulators in vivo
  • 16:20 PANEL DISCUSSION

  • What progress is being made?
  • Where the potential problems lie
  • How will treatment be affected in the future?
  • The next stage of development
  • Stephen Myers

    Stephen Myers, Acting Medical Director, Musculoskeletal Programmes, Eli Lilly & Company

    Neil Gozzard

    Neil Gozzard, Head of Pharmacology, Celltech

    Mladen Mercep

    Mladen Mercep, Inflammation-Immunology Programmes Director, PLIVA

    Elena Izmailova

    Elena Izmailova, Scientist, Millennium Pharmaceuticals

    17:00 Chairman’s Closing Remarks and Close of Day One

    +

    Jurys Great Russell Street Hotel

    16-22 Great Russell Street
    London WC1B 3NN
    United Kingdom

    Jurys Great Russell Street Hotel

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.